Abstract
Research on peripheral (blood-based) biomarkers for psychiatric illness has typically been low-throughput, and traditional case-control studies are subject to potential confounds of treatment and other exposures. Here, we leverage large-scale, high-throughput proteomics data and Mendelian Randomization (MR) to examine the causal impact of circulating proteins on neuropsychiatric phenotypes. We utilized plasma proteomics data from the UK Biobank (3,072 proteins / 34,557 individuals) and deCODE Genetics (4,719 proteins / 35,559 individuals). Significant proteomic quantitative trait loci served as MR instruments, with the most recent GWAS for schizophrenia, bipolar disorder, major depressive disorder, and cognitive task performance as phenotypic outcomes. MR revealed 109 Bonferroni-corrected causal associations (44 novel) involving 88 proteins across the four phenotypes. Several immune-related proteins, including interleukins and complement factors, stood out as pleiotropic across multiple phenotypes. Identification of causal effects for these circulating proteins suggests potential biomarkers for these conditions and offers insights for developing innovative therapeutic strategies.
Competing Interest Statement
J.F., B.S., D.B., and C.-Y.C. are employees of Biogen. The other authors declare no competing interests.
Funding Statement
The study is supported by the National Institute of Mental Health of the National Institutes of Health (NIH) under award no. R01MH117646 (T.L., principal investigator).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data and Code Availability 1. Outcome GWAS summary statistics can be downloaded from SCZ: received from PGC consortium - will be made available upon publication. BIP: https://figshare.com/ndownloader/files/40036705 MDD: https://ipsych.dk/fileadmin/ipsych.dk/Downloads/daner_MDDwoBP_20201001_2015iR15iex_HRC_MDDwoBP_iPSYCH2015i_Wray_FinnGen_MVPaf_2_HRC_MAF01.gz CTP: Received from UKBB - will be made available upon publication 2. Mendelian Randomization (MR) package (GitHub link: https://github.com/cran/MendelianRandomization ) 3. TwoSampleMR package (GitHub link: https://mrcieu.github.io/TwoSampleMR/index.html ) 4. Meta-analysis package (Github link: https://github.com/cran/metap/blob/master/R/sumlog.R) 5. EnricR (Webportal link: https://maayanlab.cloud/Enrichr/) 6. StringDB - Protein-Protein Interaction (Webportal link: https://string-db.org/ ) 7. LEUGWASR package (Github link: https://github.com/MRCIEU/ieugwasr)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revised language and formatting, but no substantive changes.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
